The Enhanced Games held its inaugural competition in Paris, France, during the weekend of April 20-22, 2026, openly permitting performance-enhancing drugs.
The event represents a fundamental shift in athletic competition by making doping the core business model. By removing the ban on banned substances, organizers aim to force society and the sporting world to confront the reality of drug enhancement.
Founder Aron D'Souza led the initiative with significant backing from venture-capital investors, including Peter Thiel’s Founders Fund [1]. The venture reached a valuation of $1.2 billion before a single race took place [2]. To attract competitors, the games offered million-dollar prize bonuses [3].
Organizers said the event is intended to create a new commercial market for performance-enhancing pharmaceuticals [4]. This approach contrasts with the traditional Olympic model, which mandates strict drug testing and bans the use of steroids and peptides.
The competition seeks to move beyond the traditional restrictions of sport, framing the use of pharmaceutical enhancement as a legitimate pursuit of human potential [4]. By providing a legal framework for doping, the organizers said they are providing a safer environment for athletes who already use these substances in secret [4].
Critics have raised concerns regarding the safety of the substances used and the potential for the event to encourage dangerous medical practices. Despite these concerns, the financial backing suggests a high level of investor interest in the intersection of biotechnology and professional athletics [2].
“The Enhanced Games is a competition that openly permits performance‑enhancing drugs.”
The Enhanced Games attempts to disrupt the century-old paradigm of 'natural' athletics by treating human performance as a biotechnological frontier. By securing a billion-dollar valuation and high-profile venture capital, the event transitions doping from a clandestine cheating scandal into a transparent, commercialized industry. This creates a direct conflict with global sporting bodies and may accelerate the commercial development of performance-enhancing pharmaceuticals outside of traditional medical oversight.
